795. Deputy Albert Dolan asked the Minister for Health if she has engaged with the Minister for Finance regarding the application of VAT to certain vaccines and prescribed medical products; if changes are under consideration; and if she will make a statement on the matter. [51289/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Albert Dolan under the heading Medicinal Products.
26 questions match, newest first.
421. Deputy Albert Dolan asked the Minister for Health if she will provide an update on the consideration by the HSE senior leadership team of the reimbursement application for givinostat; whether a decision has now been reached following the recommendation submitted by the Drugs Group on 9 June 2026; and if she will make a statement on the matter. [48421/26]
466. Deputy Albert Dolan asked the Minister for Health the reason skyclarys has not been included on the agenda for the recent HSE Drugs Group meeting held in June 2026; when the drug will be considered by the Drugs Group; the timeline for a decision on its prioritisation within the reimbursement process; and the measures being taken to ensure there are no further avoidable delays in progressing access to skyclarys f…
838. Deputy Albert Dolan asked the Minister for Health whether she is satisfied that current reimbursement timelines for orphan medicines align with the commitments on timely and equitable access set out in the National Rare Disease Strategy 2025–2030; the measures that are being taken to address delays in cases where EMA-approved treatments, including those for Friedreich’s ataxia, remain unavailable to patients in …
473. Deputy Albert Dolan asked the Minister for Health the number of schools currently registered under the Medicines for Listed Organisations framework to hold emergency medicines such as adrenaline auto-injectors for the treatment of severe allergic reactions; and if she will make a statement on the matter. [23373/26]
1750. Deputy Albert Dolan asked the Minister for Health the status of the HSE and Department of Health assessment of Omaveloxolone (Skyclarys) for the treatment of Friedreich’s Ataxia; the timeline for completing the reimbursement process; the engagement that has taken place with patient representatives and clinical experts; and if she will make a statement on the matter. [18744/26]
1751. Deputy Albert Dolan asked the Minister for Health the specific steps the HSE is taking to ensure that the time-critical nature of Friedreich’s Ataxia is fully recognised and reflected in the ongoing price negotiations for the reimbursement of Skyclarys; and if she will make a statement on the matter. [18745/26]
1752. Deputy Albert Dolan asked the Minister for Health the way in which the commitments set out in the National Rare Disease Strategy 2025–2030, particularly regarding timely access to approved therapies for rare disease patients, are being applied to the current reimbursement process for Skyclarys for the treatment of Friedreich’s Ataxia; and if she will make a statement on the matter. [18746/26]
1753. Deputy Albert Dolan asked the Minister for Health the way in which the 180-day decision timeline contained within the 2026 IPHA Framework Agreement is being implemented in the case of Skyclarys, given that over 570 days have now elapsed since the reimbursement application was submitted; and if she will make a statement on the matter. [18747/26]
998. Deputy Albert Dolan asked the Minister for Health if she will introduce a national scheme for improved access to emergency anaphylaxis medication, including adrenaline auto-injectors, along with structured training and guidance for schools, childcare providers and public settings; and if she will make a statement on the matter. [69648/25]
1000. Deputy Albert Dolan asked the Minister for Health if she will work with the Minister for Education and Youth to ensure that all schools have access to stock adrenaline auto-injectors, rather than relying on individual students and their families to supply them; the measures being taken to provide mandatory, standardised training for teachers and school staff so they feel confident and safe in administering auto…
1995. Deputy Albert Dolan asked the Minister for Health further to Parliamentary Question No. 766 of 21 October 2025, if she will provide a detailed update on the progress of the best value medicines programme in achieving its stated target of at least 80% of individuals being in receipt of the best value medicine; if she will provide a breakdown of uptake levels by each target area; and if she will make a statement …
1996. Deputy Albert Dolan asked the Minister for Health if there are any policy proposals or changes planned that will assist how the best value medicines programme contributes to reducing the financial burden on the HSE’s medicines budget and assists in securing access for patients to new and innovative treatments; and if she will make a statement on the matter. [59593/25]
1997. Deputy Albert Dolan asked the Minister for Health to outline the expected policy changes planned to achieve the Programme for Government commitment to “ensuring that patients have access to new innovative new medicines and treatments as quickly as possible”; and if she will make a statement on the matter. [59594/25]
757. Deputy Albert Dolan asked the Minister for Health the total budget allocated for spending on medicines by the HSE in each of the past five years; the outturn expenditure on medicines in each of those years; the projected allocation for 2025; and if she will make a statement on the matter. [56629/25]
758. Deputy Albert Dolan asked the Minister for Health the HSE expenditure on medicines for each of the past five years, by category (including high-tech medicines, biologics, biosimilars, generics and community drug schemes); the projected spend for 2025; and if she will make a statement on the matter. [56630/25]
759. Deputy Albert Dolan asked the Minister for Health her plans to revise the national uptake targets for each medicine in the best value medicines programme; if so, the targets and the date she expects them to be met; the reasons for the targets not being met; and if she will make a statement on the matter. [56631/25]
760. Deputy Albert Dolan asked the Minister for Health the uptake rates for each best value medicine by hospital group or clinical site; to identify those that are underperforming against the targets set by the HSE to save money for the HSE; the specific actions she will take to bring prescribing into line with HSE policy; and if she will make a statement on the matter. [56632/25]
761. Deputy Albert Dolan asked the Minister for Health the total additional cost to the HSE resulting from sub-optimal uptake of best value medicines since the programme was introduced; and the impact this has had on access to new medicines for patients; and if she will make a statement on the matter. [56633/25]
762. Deputy Albert Dolan asked the Minister for Health if she is aware of clinicians that continue to prescribe higher-cost originator medicines contrary to the HSE's best value medicines guidance; the measures which will be introduced to ensure adherence; and if she will make a statement on the matter. [56634/25]
763. Deputy Albert Dolan asked the Minister for Health if she will consider introducing sanctions for hospital groups that fail to meet best value medicines uptake requirements, or alternatively strengthening gain-share incentives to ensure the savings target is delivered; and if she will make a statement on the matter. [56635/25]
764. Deputy Albert Dolan asked the Minister for Health the communication and support provided to patients being switched to best value medicines; the monitoring which has been undertaken on patient outcomes and acceptance of switching; and if she will publish the data annually; and if she will make a statement on the matter. [56636/25]
765. Deputy Albert Dolan asked the Minister for Health the way in which the best value medicines programme contributes to reducing the financial burden on the HSE's medicines budget and assists in securing access for patients to new and innovative treatments; and if she will make a statement on the matter. [56637/25]
766. Deputy Albert Dolan asked the Minister for Health if she will report on the progress of the best value medicines programme in achieving its stated target of at least 80% of individuals being in receipt of the best value medicine; if she will provide a breakdown of uptake levels by each target area; and if she will make a statement on the matter. [56638/25]
402. Deputy Albert Dolan asked the Minister for Health if she will provide an update on the current status of the approval process for the drug givinostat for patients with Duchenne muscular dystrophy; if consideration is being given to its inclusion in an early access programme, similar to those operating in the United Kingdom and the United States; and if she will make a statement on the matter. [33312/25]